Michael J. Birrer, MD of Massachusetts General Hospital discusses current actionable mutations in advanced ovarian cancer at SGO 2016.
Transcription:
I think all of the genes and there’s probably between twenty and thirty of them are that are looking to Fanconi DNA repair pathway I would be important to look at they may ascribe homologous recombination deficiency to the tumor in which case those patients would benefit from apartment a better doesn’t have to be at the time of initial diagnosis. But knowing it would be important in the recurrent setting that the patient that would be a candidate for parking part agents either on trial. I or now authorized standard care.